Anorectic

History

Used on a short-term basis clinically to treat obesity, some appetite suppressants are also available over-the-counter. Several appetite suppressants are based on a mix of natural ingredients, mostly using green tea as its basis, in combination with other plant extracts, such as fucoxanthin, found naturally in seaweed. Drugs of this class are frequently stimulants of the phenethylamine family, related to amphetamine.

The German and Finnish militaries issued amphetamines (Pervitin) to soldiers commonly during the Second World War. Similarly, the UK military was supplied with more than 72 million Benzedrine tablets and the US military with an approximately equal amount for situations, in which fatigue was not deemed to be an acceptable option. Following the war, large amphetamine surpluses were redirected for use on the black and the civilian market. Indeed, amphetamine itself was sold commercially as an appetite suppressant until it was outlawed in most parts of the world in the late 1950s because of safety issues. Many amphetamines produce side effects, including addiction, tachycardia and hypertension, making prolonged unsupervised use dangerous.

Public health concerns

Epidemics of fatal pulmonary hypertension and heart valve damage associated with pharmaceutical anorectic agents have led to the withdrawal of products from the market. This was the case with aminorex in the 1960s, and again in the 1990s with fenfluramine (see: Fen-phen). Likewise, association of the related appetite suppressant phenylpropanolamine with hemorrhagic stroke led the Food and Drug Administration (FDA) to request its withdrawal from the market in the United States in 2000, and similar concerns regarding ephedrine resulted in an FDA ban on its inclusion in dietary supplements in 2004. A Federal judge later overturned this ban in 2005 during a challenge by supplement maker Nutraceuticals. It is also debatable as to whether the ephedrine ban had more to do with its use as a precursor in methamphetamine manufacture rather than health concerns with the ingredient as such.

Non-pharmacological alternatives

Weight loss effects of water have been subject to some scientific research as a potential non-pharmacological approach. Drinking water prior to each meal may help in appetite suppression. Consumption of 500 mL of water 30 minutes before meals has been correlated with modest weight loss (1 –) in obese men and women over a period of 8 to 12 weeks.

Refeeding syndrome

Main article: Refeeding syndrome

Refeeding syndrome (RFS) is a metabolic disturbance which occurs as a result of reinstitution of nutrition in people and animals who are starved, severely malnourished, or metabolically stressed because of severe illness. When too much food or liquid nutrition supplement is eaten during the initial four to seven days following a malnutrition event, the production of glycogen, fat and protein in cells may cause low serum concentrations of potassium, magnesium and phosphate. The electrolyte imbalance may cause neurologic, pulmonary, cardiac, neuromuscular, and hematologic symptoms—many of which, if severe enough, may result in death.

Refeeding syndrome can occur when someone who has not eaten for a long time, starts eating normal or even binging amounts of food.

Individuals with drug abuse who begin to reintroduce normal eating habits after a period of malnutrition may be at increased risk for refeeding syndrome.

List of anorectics

Numerous pharmaceutical compounds are marketed as appetite suppressants.

The following drugs are listed as "centrally-acting antiobesity preparations" in the Anatomical Therapeutic Chemical Classification System:

• Amfepramone (also known as diethylpropion)
• Bupropion and naltrexone (combination)
• Cathine
• Clobenzorex
• Dexfenfluramine† (the D-enantiomer of fenfluramine; withdrawn for the same reason as its racemate)
• Ephedrine (combinations)
• Etilamfetamine
• Fenfluramine† (one of the two components [the other being phentermine] of Fen-phen. Since discontinued to its potential for causing valvulopathies and pulmonary hypertension)
• Lorcaserin (withdrawn in the United States by the FDA due to an increased risk of cancer)
• Mazindol
• Mefenorex
• Phentermine
• Sibutramine† (in some countries withdrawn from the market because of concerns regarding its cardiovascular effects)
• Topiramate

The following are listed as appetite depressants by MeSH, an index of medical journal articles and books.

• Benfluorex (removed from the market by the EMA due to increased risk of heart disease)
• Butenolide
• Diethylpropion
• FG-7142
• Phenmetrazine† (withdrawn in some countries due to the danger of addiction)
• Phentermine
• Phenylpropanolamine
• Pyroglutamyl-histidyl-glycine
• Sibutramine

Other compounds with known appetite suppressant activity include:

• Amphetamine-Dextroamphetamine is known to hamper appetite. Amphetamine-Dextroamphetamine is used to treat Attention deficit hyperactivity disorder (ADHD) and is usually under the trade name "Adderall" or "Mydayis".
• Amphetamine sulfate (also known as amfetamine) – US FDA-approved for the treatment of exogenous obesity under the brand name "Evekeo".
• Methylphenidate
• Cocaine
• Caffeine
• Glucomannan
• Leptin
• Lisdexamphetamine - US FDA approved for the treatment of binge-eating disorder in adults under the brand name "Vyvanse".
• Methamphetamine hydrochloride – USFDA-approved for the treatment of obesity (as a short-term) under the brand name "Desoxyn".
• Nicotine
• Liraglutide as brand name Saxenda
• Semaglutide (brand name Ozempic/Wegovy) GLP-1 agonist
• Tirzepatide (Brand Name Mounjaro, Zepbound)
• Metformin
• Opiates/opioids such as heroin, morphine, codeine, oxycodone, fentanyl, etc.

References

References

1. (2012). "Foye's Medicinal Chemistry". Lippincott Williams & Wilkins.
2. (2025-04-27). "Fucoxanthin Benefits: 7 Powerful Health Effects You Need to Know".
3. [[:fi:Pervitiini]]
4. Ulrich, Andreas. (May 6, 2005). "The Nazi Death Machine: Hitler's Drugged Soldiers". Spiegel Online.
5. Bett, W. R.. (1946-08-01). "Benzedrine Sulphate in Clinical Medicine". Postgraduate Medical Journal.
6. (June 2013). "Amphetamine, past and present – a pharmacological and clinical perspective". Journal of Psychopharmacology.
7. (1996). "Appetite-Suppressant Drugs and the Risk of Primary Pulmonary Hypertension". New England Journal of Medicine.
8. (1999). "Aminorex to Fen/Phen : An Epidemic Foretold". Circulation.
9. (2013). "Pre-meal water consumption for weight loss". Australian Family Physician.
10. (2009). "Water Consumption Increases Weight Loss During a Hypocaloric Diet Intervention in Middle-aged and Older Adults". Obesity.
11. (2014). "Effect of excessive water intake on body weight, body mass index, body fat, and appetite of overweight female participants". Journal of Natural Science, Biology and Medicine.
12. (June 2008). "Refeeding syndrome: what it is, and how to prevent and treat it". BMJ.
13. (2015-12-01). "Restricted versus continued standard caloric intake during the management of refeeding syndrome in critically ill adults: a randomised, parallel-group, multicentre, single-blind controlled trial". The Lancet Respiratory Medicine.
14. (2011). "Complications of emergency refeeding in anorexia nervosa: case series and review". Acute Medicine.
15. "Refeeding Syndrome".
16. [http://www.whocc.no/atc_ddd_index/?code=A08AA ATC/DDD Index]
17. (2020-02-13). "FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market". FDA.
18. {{MeshPharmaList. 82001067
19. (December 12, 2009). "European Medicines Agency recommends withdrawal of benfluorex from the market in European Union".
20. (2018-06-01). "Attention deficit hyperactivity disorder (ADHD) - Treatment".
21. "Adderall Oral: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD".
22. (April 2014). "Evekeo Prescribing Information". Arbor Pharmaceuticals LLC.
23. (1988). "Substitution and cross-tolerance profiles of anorectic drugs in rats trained to detect the discriminative stimulus properties of cocaine". Psychopharmacology.
24. (December 2017). "Caffeine, coffee, and appetite control: a review". International Journal of Food Sciences and Nutrition.
25. (September 2020). "Effects of glucomannan supplementation on weight loss in overweight and obese adults: A systematic review and meta-analysis of randomized controlled trials". Obesity Medicine.
26. (November 2021). "Konjac glucomannan molecular and rheological properties that delay gastric emptying and improve the regulation of appetite". Food Hydrocolloids.
27. (January 2007). "The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review". Obesity Reviews.
28. (August 28, 2023). "FDA approves multiple generics of ADHD and BED treatment". FDA.
29. (December 2013). "Desoxyn Prescribing Information". United States Food and Drug Administration.
30. "Why smoking makes you lose weight and no, it's not a good idea". The Times of India.